Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Sell
19
CYCN Quote, Financials, Valuation and Earnings
Last price:
$1.21
Seasonality move
:
-16.84%
Day range:
$1.30 - $1.37
52-week range:
$1.28 - $6.25
Dividend yield:
0%
P/E ratio:
3.37x
P/S ratio:
1.35x
P/B ratio:
0.54x
Volume:
32.9K
Avg. volume:
55.1K
1-year change:
-59.34%
Market cap:
$5.1M
Revenue:
$2M
EPS (TTM):
-$0.76
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Cyclerion Therapeutics, Inc. has 5825.93% upside to fair value with a price target of -- per share.
CYCN vs. S&P 500
-
Over the past 5 trading days, Cyclerion Therapeutics, Inc. has underperformed the S&P 500 by -9.43% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Cyclerion Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cyclerion Therapeutics, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Cyclerion Therapeutics, Inc. reported revenues of $875K.
Earnings Growth
-
Cyclerion Therapeutics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Cyclerion Therapeutics, Inc. reported earnings per share of -$0.30.
Enterprise value:
570.4K
EV / Invested capital:
0.06x
Price / LTM sales:
1.35x
EV / EBIT:
--
EV / Revenue:
0.20x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-0.41x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-22.86%
Net Income Margin (TTM):
-77.02%
Return On Equity:
-25.03%
Return On Invested Capital:
-25.03%
Operating Margin:
-114.97%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $194K | $2.9M | $194K | $875K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$12.3M | -$5.9M | -$3.6M | -$1.1M | -$1M | |
| EBITDA | -$12.3M | -$5.9M | -$3.6M | -$1.1M | -$1M | |
| Diluted EPS | -$72.43 | -$2.12 | -$0.76 | -$0.29 | -$0.30 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $63.7M | $21.7M | $9.9M | $3.5M | $5.1M | |
| Total Assets | $67.7M | $25.1M | $15.2M | $8.9M | $10.4M | |
| Current Liabilities | $11.4M | $8.5M | $2.3M | $700K | $877K | |
| Total Liabilities | $11.4M | $8.5M | $2.3M | $700K | $877K | |
| Total Equity | $56.4M | $16.5M | $12.9M | $8.2M | $9.5M | |
| Total Debt | $3.5M | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$26.7M | -$6.2M | -$1.4M | -$1.7M | -$264K | |
| Cash From Investing | $10.4M | -- | -- | -- | -- | |
| Cash From Financing | $5M | -- | $3.1M | -- | $1.8M | |
| Free Cash Flow | -$26.7M | -$6.2M | -$1.4M | -$1.7M | -$264K | |
CYCN
Sector
Market Cap
$5.1M
$28.2M
Price % of 52-Week High
21.6%
50.25%
Dividend Yield
0%
0%
Shareholder Yield
-36.13%
-1.54%
1-Year Price Total Return
-59.34%
-18.1%
Beta (5-Year)
0.945
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.47
200-day SMA
Sell
Level
$2.52
Bollinger Bands (100)
Sell
Level
1.63 - 2.55
Chaikin Money Flow
Buy
Level
2.5M
20-day SMA
Sell
Level
$1.56
Relative Strength Index (RSI14)
Sell
Level
34.21
ADX Line
Sell
Level
19.19
Williams %R
Buy
Level
-89.7632
50-day SMA
Sell
Level
$1.70
MACD (12, 26)
Sell
Level
-0.08
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
315.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-32.9296)
Buy
CA Score
(Annual)
Level (-0.0894)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (9.4594)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
Stock Forecast FAQ
In the current month, CYCN has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CYCN average analyst price target in the past 3 months is --.
-
Where Will Cyclerion Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cyclerion Therapeutics, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Cyclerion Therapeutics, Inc.?
Analysts are divided on their view about Cyclerion Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cyclerion Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is Cyclerion Therapeutics, Inc.'s Price Target?
The price target for Cyclerion Therapeutics, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CYCN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cyclerion Therapeutics, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CYCN?
You can purchase shares of Cyclerion Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cyclerion Therapeutics, Inc. shares.
-
What Is The Cyclerion Therapeutics, Inc. Share Price Today?
Cyclerion Therapeutics, Inc. was last trading at $1.21 per share. This represents the most recent stock quote for Cyclerion Therapeutics, Inc.. Yesterday, Cyclerion Therapeutics, Inc. closed at $1.35 per share.
-
How To Buy Cyclerion Therapeutics, Inc. Stock Online?
In order to purchase Cyclerion Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CYCN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CYCN
Sector
P/E ratio
3.37x
23.92x
PEG ratio
-0.01x
-0.01x
P/B ratio
0.54x
1.83x
Price / LTM sales
1.35x
1.61x
Growth Metrics
CYCN
Sector
Revenue growth
351.03%
4.6%
Earnings growth
-5.73%
10.88%
Revenue (5-year growth)
-15%
6.46%
Earnings forecast
--
-$0.21
Profitability
CYCN
Sector
Profitability FY 2024
--
$3.5M
Return on invested capital
-25.03%
-31.84%
Return on assets
-22.86%
-27.96%
Return on equity
-25.03%
-37.63%
Earnings Date
Last Earnings Date
Dec
30
Next Earnings Date
Dec
30
Estimated Next Earnings Date
Mar
31
Balance Sheet
CYCN
Sector
Total cash
$4.6M
$26.3M
Short term investments
--
$25.7M
Total assets
$9.6M
$76.9M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 29
Galecto, Inc. [GLTO] is down 12.13% over the past day.
Sell
20
SMX alert for Dec 29
SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.
Sell
11
CDNAF alert for Dec 29
Canadian Tire Corp. Ltd. [CDNAF] is up 11.94% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
